Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.45 |
| ▸ | CNR1 | P21554 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25027294 | 1.00 | CNR2 (0.45) | CNR2CNR1POLBL3MBTL1ALOX5AP | |
| SCHEMBL25024820 | 0.91 | CNR2 (0.47) | CNR2CNR1POLBL3MBTL1ALOX5AP | |
| SCHEMBL25026492 | 0.82 | LIPC (0.40) | HIF1AEPAS1ALDH1A1NPSR1 | |
| SCHEMBL25027139 | 0.81 | KIF11 (0.40) | ALDH1A1NPSR1 | |
| SCHEMBL25026486 | 0.81 | AR (0.35) | ALDH1A1NPSR1 | |
| SCHEMBL31053872 | 0.81 | SRPK1 (0.40) | POLBALDH1A1ALOX12NPSR1SRPK1 | |
| SCHEMBL25024966 | 0.81 | SRPK1 (0.40) | POLBALDH1A1ALOX12NPSR1SRPK1 | |
| SCHEMBL25026972 | 0.80 | GAA (0.39) | NPSR1 | |
| SCHEMBL30137501 | 0.79 | SMN1; SMN2 (0.54) | CNR2CNR1POLBL3MBTL1HIF1A | |
| SCHEMBL25026295 | 0.78 | LMNA (0.48) | CNR2CNR1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171417-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2025-05-29 | — | — | US | disclosed |
| CN-118475567-A | Heterocyclic derivative, composition and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171417-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | AR, BCKDK, CYP11B2 | CNR2 255/4885CNR1 265/4885POLB 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.